LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Kodu・Aktsiate loetelu・Novavax Inc

Novavax Inc

Suletud

SektorTervishoid

6.58 -1.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.53

Max

6.59

Põhinäitajad
By Trading Economics
Sissetulek	-309M -202M
Müük	-169M 70M
P/E Sektori keskmine	3.373 77.671
Aktsiakasum	-1.25
Kasumimarginaal	-287.287
Töötajad	952
EBITDA	-312M -191M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+52.21% upside

Turustatistika
By TradingEconomics
Turukapital	-183M 1.1B
Eelmine avamishind	8.22
Eelmine sulgemishind	6.58

Uudiste sentiment

By Acuity

53%

47%

290 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

5.692 / 6.039 Toetus ja vastupanu

Novavax Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2025, 17:06 UTC

Suurimad hinnamuutused turgudel

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31. märts 2025, 14:19 UTC

Suurimad hinnamuutused turgudel

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

4. veebr 2025, 18:52 UTC

Suurimad hinnamuutused turgudel

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

19. mai 2025, 14:30 UTC

Peamised uudised

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

19. mai 2025, 13:27 UTC

Peamised uudised

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

8. mai 2025, 17:55 UTC

Tulu

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8. mai 2025, 15:12 UTC

Tulu

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

28. apr 2025, 17:04 UTC

Tulu

Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. -- Barrons.com

30. dets 2024, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

Võrdlus sarnastega

Hinnamuutus

Novavax Inc Prognoos

Hinnasiht

By TipRanks

52.21% tõus

12 kuu keskmine prognoos

Keskmine 10 USD 52.21%

Kõrge 18 USD

Madal 6 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Novavax Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Novavax Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.692 / 6.039Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

290 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.